Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Pulmonx (LUNG) over the last 6 years, with Q3 2025 value amounting to $37.0 million.

  • Pulmonx's Non-Current Debt fell 30.16% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 30.16%. This contributed to the annual value of $34.0 million for FY2024, which is 309.78% down from last year.
  • Pulmonx's Non-Current Debt amounted to $37.0 million in Q3 2025, which was down 30.16% from $37.0 million recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Non-Current Debt registered a high of $37.2 million during Q1 2023, and its lowest value of $179000.0 during Q4 2021.
  • For the 5-year period, Pulmonx's Non-Current Debt averaged around $23.8 million, with its median value being $32.0 million (2024).
  • As far as peak fluctuations go, Pulmonx's Non-Current Debt tumbled by 6826.24% in 2021, and later surged by 952793.3% in 2022.
  • Pulmonx's Non-Current Debt (Quarter) stood at $179000.0 in 2021, then surged by 9527.93% to $17.2 million in 2022, then soared by 103.6% to $35.1 million in 2023, then fell by 3.1% to $34.0 million in 2024, then rose by 8.89% to $37.0 million in 2025.
  • Its Non-Current Debt stands at $37.0 million for Q3 2025, versus $37.0 million for Q2 2025 and $29.4 million for Q1 2025.